The Female Health Company to Present at Sidoti's Semi-Annual New York Micro-Cap
Conference
CHICAGO, Jan. 2, 2013 /PRNewswire via COMTEX/ -- The Female Health Company
(nasdaq-cm:FHCO), which manufactures and markets the FC2 Female Condom, today
announced that O.B. Parrish, CEO, and Michele Greco, CFO, are scheduled to make a
presentation at the Sidoti Semi-Annual New York Micro-Cap Conference at 2:50 PM
Eastern Time on Monday, January 7, 2013, in the Estate 1 Winter Garden Room. The
Company's executives will also meet with investors to discuss the Company's
ongoing operations. The conference will be held at the Grand Hyatt New York Hotel
in midtown Manhattan.
About Sidoti & Company, LLC
Sidoti & Company, LLC, founded in 1999, continues to set the Wall Street standard
for independent small-cap equity research, while rapidly becoming a driving force
in micro-cap research, launching coverage of more than 400 equities of $250
million market cap or less since mid-2010. Its analysts mine dozens of industries
to provide unbiased, institutional-quality research focusing on the investment
merits of profitable companies at a sub-$3 billion market cap, and its goal was
to extend coverage to 500 micro-cap equities by the end of 2012.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets
the FC2 Female Condom (FC2), which is available in the U.S. and approximately 138
other countries globally. The Company owns certain worldwide rights to the FC2
Female Condom, including patents that have been issued by the U.S., the European
Union, Canada, Australia, South Africa, Japan, The People's Republic of China,
Spain, Mexico, Greece, Turkey and the African Regional Intellectual Property
Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho,
Malawi, Mozambique, Namibia, Sierra Leone, Somalia, Sudan, Swaziland, Uganda,
United Republic of Tanzania, Zambia and Zimbabwe. FC2 patent applications are
pending in various countries. The FC2 Female Condom is the only available
FDA-approved product controlled by a woman that offers dual protection against
sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The
World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this release which are not historical facts are forward-looking
statements based upon the Company's current plans and strategies, and reflect the
Company's current assessment of the risks and uncertainties related to its
business, including such things as product demand and market acceptance; the
economic and business environment and the impact of government pressures;
currency risks; capacity; efficiency and supply constraints; and other risks
detailed in the Company's press releases, shareholder communications and
Securities and Exchange Commission filings. Actual events affecting the Company
and the impact of such events on the Company's operations may vary from this
currently anticipated.
For more information about the Female Health Company visit the Company's website
at femalehealth.com and femalecondom.org. If you would like
to be added to the Company's e-mail alert list, please send an e-mail to
FHCInvestor@femalehealthcompany.com. |
